SYNAPS Dx announces it will present “Physicians’ Assessment of the Clinical Utility of a Novel Test to Diagnose Alzheimer’s Disease (AD),” at the ISPOR Annual Conference. The implicit preference study indicates that 90% of physicians would routinely use the results of DISCERN™, a diagnostic test that assesses the factors directly related to the formation of synaptic connections in the brain impacting loss of memory and cognition in people living with AD as well as regulators of amyloid plaque and tau formation, hallmarks of AD at autopsy.